erzotabart

{
  "id": "MLC-T-ONC-013428",
  "term": "erzotabart",
  "field": "Oncology and biomedicine",
  "definition": "A hexamerization-enhanced human immunoglobulin G1 (IgG1) monoclonal antibody that targets the cell surface glycoprotein CD-38 and carries the E430G mutation, with potential immunomodulating and antineoplastic activities. Upon administration, erzotabart targets and binds to CD38 on CD38-positive tumor cells, thereby forming antibody hexamers through increased intermolecular Fc-Fc interactions upon antigen binding. This may trigger direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by GEN3014 induces downmodulation of CD38, inhibits CD38 cyclase activity, and may abrogate immune suppression in the tumor microenvironment (TME). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.",
  "synonyms": [
    "HexaBody-CD38",
    "anti-CD38 monoclonal antibody GEN3014"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/erzotabart/"
}